Loading component...

Voluntary nationwide recall: Atovaquone (Bionpharma – September)

Oct. 2024Pharmacy Updates

Bionpharma Inc. is recalling one lot, lot 2310083, of Atovaquone Oral Suspension, 750 mg/mL. Atovaquone is used to prevent a fungal infection called pneumocystis jirovecii pneumonia in adults and adolescents age 13 and older.

This drug is being recalled because Cohnella bacteria was found in the product. Using this contaminated drug can cause life-threatening swelling of the heart and permanent damage to the body’s soft tissue.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Atovaquone, you should stop using the product and return it to the place of purchase.

As of Sept. 17, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Bionpharma at 1-888-235-2466. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Voluntary nationwide recall: Alcohol Pads (Cardinal – March)

Cardinal Health is recalling multiple lots of Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol). Alcohol prep pads are used for external cleansing of the skin.
Mar. 2026Pharmacy Updates

Medical device correction: Omnipod 5 (Insulet – March 2026)

Insulet Corporation has announced a medical device correction for certain Omnipod 5 pods. These pods are wearable devices that are used to deliver insulin.
Mar. 2026Pharmacy Updates

Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?

In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.
Mar. 2026Education/Webinars

Loading component...